Sanofi SA ADR
SNY: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$93.00 | Ffnx | Ccfltdfl |
Led by Dupixent, Sanofi's Solid Immunology Position Helps Support Steady Long-Term Growth
Business Strategy and Outlook
Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset upcoming patent losses.